Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

2 results

Results by year

Filters applied: . Clear all
Page 1
I-Tositumomab in lymphoma.
Cheung MC, Maceachern JA, Haynes AE, Meyer RM, Imrie K; Members of the Hematology Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care. Cheung MC, et al. Curr Oncol. 2009 Sep;16(5):32-47. Curr Oncol. 2009. PMID: 19862360 Free PMC article.
Initial studies of (131)I-tositumomab in non-Hodgkin lymphoma (NHL) have suggested benefit in patients with relapsed or refractory indolent disease. However, the routine adoption of this agent is tempered by concerns about associated toxicities and unclear long-term benefi …
Initial studies of (131)I-tositumomab in non-Hodgkin lymphoma (NHL) have suggested benefit in patients with relapsed or refractory indolent …
Temozolomide for the treatment of metastatic melanoma.
Quirbt I, Verma S, Petrella T, Bak K, Charette M; Members of the Melanoma Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. Quirbt I, et al. Curr Oncol. 2007 Feb;14(1):27-33. doi: 10.3747/co.2007.98. Curr Oncol. 2007. PMID: 17576461 Free PMC article.
To provide treatment recommendations for this new agent, the Melanoma Disease Site Group (dsg) of Cancer Care Ontario's Program in Evidence-Based Care (pebc) decided to review the available literature on single-agent temozolomide and on temozolomide in combin …
To provide treatment recommendations for this new agent, the Melanoma Disease Site Group (dsg) of Cancer Care Ontario's …